ClinicalTrials.gg
RecruitingNCT04078555Updated Feb 20, 2024

A Study to Evaluate ENERGI-F703 GEL in Venous Leg Ulcer

A Phase 2 interventional study of ENERGI-F703 GEL and ENERGI-F703 GEL matched vehicle in Venous Leg Ulcer, sponsored by Energenesis Biomedical Co., Ltd.. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Energenesis Biomedical Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, phase II, multi-centered study to evaluate the efficacy and safety of ENERGI-F703 GEL in subjects who are ≥ 20 years old with venous leg ulcer (VLU). Subjects will be recruited from multiple sites in Taiwan. The treatment period will be 84 days with another 84-day follow-up period.

02

Conditions studied

  • Venous Leg Ulcer

Browse trials for

03

In context

Varicose Ulcer

371 studies on the registry are indexed under Varicose Ulcer; 75 are open to participants now.

This study's planned enrollment of 80 is above the median of 60 across 310 interventional studies indexed under Varicose Ulcer.

Browse Varicose Ulcer studies →

Lead sponsor

Energenesis Biomedical Co., Ltd. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. With either gender aged at least 20 years old
  2. With venous reflux >0.1 sec measured by duplex ultrasound imaging dated within 6 months prior to the Screening visit
  3. With at least one venous ulcer on the lower leg (knee to ankle inclusive) and not healing for at least 4 weeks. The ulcer with the largest surface area will be selected as target ulcer. If two or more ulcers have the largest size, the one with the longest duration will be selected
  4. With the target ulcer size of 2 cm2 to 50 cm2
  5. Target VLU involves a full thickness skin loss, but without exposure of tendon, muscle, or bone
  6. Target VLU should be free of any necrosis or infection in any soft tissue and bone tissue
  7. Able to tolerate compression therapy
  8. Subject has signed the written form

Exclusion criteria

Exclusion Criteria:

  1. Target VLU With active cellulitis or osteomyelitis
  2. With target ulcer size decreased by at least 30% after 2 weeks of standard care
  3. With poor nutritional status (albumin \< 2g/dl), poor diabetic control ( > 12%), a leukocyte counts \< 2,000/mm3, abnormal liver function (, ALT>3 × ) tests within 14 days prior to Screening visit or 28 days prior to Randomization visit
  4. Requiring treatment with chemotherapeutic agents
  5. With known or suspected to any ingredients of IP and matched vehicle
  6. With coronary heart disease with myocardial infarction, coronary artery bypass graft (CABG), or percutaneous transluminal coronary angioplasty (PTCA) within 3 months prior to Screening visit
  7. (1) Female subject of who:

    • is lactating; or
    • has positive pregnancy test result at eligibility checking; or
    • refuses to adopt at least one form of from signing to the end of study

    Note:

    Acceptable forms include:

    Established use of oral, injected or implanted hormonal methods of contraception. Placement of an intrauterine device (IUD) or intrauterine system (IUS).Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or cervical/vault caps)

    7(2) Male subject with female spouse/partners who are of childbearing potential refuses to adopt at least one form of birth control (at least one of which must be a barrier method) from signing informed consent to the end of study)

  8. With ankle brachial index (ABI) \< 0.6
  9. Enrollment in any drug trial within 4 weeks before entering this study
  10. With any condition judged by the investigator that entering the trial may be detrimental to the subject
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    ENERGI-F703 GEL

    topical application on target venous leg ulcer, twice daily

    Drug: ENERGI-F703 GEL

  • Placebo comparator
    ENERGI-F703 GEL matched vehicle

    topical application on target venous leg ulcer, twice daily

    Drug: ENERGI-F703 GEL matched vehicle

Interventions

  • DrugENERGI-F703 GEL

    The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first. The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size.

  • DrugENERGI-F703 GEL matched vehicle

    The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first. The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size.

06

What researchers measure

Primary outcomes

  1. Incidence of complete ulcer closure

    Complete wound closure is defined as 100% skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visit 2 weeks apart.

    Time frame: Day -21 to Day 99

Secondary outcomes

  1. Percentage change in target ulcer area from baseline to each post-treatment visit

    Time frame: Day -21 to Day 85

  2. Time-to-Complete ulcer closure of target ulcer

    Complete wound closure is defined as 100% skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visit 2 weeks apart.

    Time frame: Day -21 to Day 99

  3. The accumulated confirmed target ulcer closure incidence at each of the post-treatment visit

    Complete wound closure is defined as 100% skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visit 2 weeks apart.

    Time frame: Day -21 to Day 85

  4. Incidence of vital signs abnormalities

    Vital signs measurement will consist of systolic/diastolic blood pressure, respiratory rate, pulse rate or heart rate, and body temperature.

    Time frame: Day -21 to Day 169

  5. Incidence of physical examination abnormalities

    Physical examination will include the following items: general appearance, skin, eyes, ears, nose, throat, head and neck, heart, chest and lungs, abdomen, extremities, lymph nodes, musculoskeletal, neurological and others.

    Time frame: Day -21 to Day 169

  6. Incidence of laboratory examination results abnormalities

    The laboratory examinations include Hematology tests (CBC), Biochemistry (AST, ALP, ALT, serum creatinine, BUN, albumin and fasting glucose) and Urinalysis (pH, glucose, RBC, WBC and protein).

    Time frame: Day -21 to Day 169

  7. Incidence of AEs and SAEs

    Time frame: Day -21 to Day 169

07

Study locations

1 of 1 sites recruiting
  • Shin Kong Wu Ho-Su Memorial Hospital
    Taipei, Taiwan
    Recruiting
    • Cha-Chun Chen, MD · Contact
    • Cha-Chun Chen, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Mar 2025, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2019
First posted
Sep 6, 2019
StartActual
Jul 26, 2022
Primary completionEst.
Mar 15, 2025
CompletionEst.
Jun 15, 2025
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04078555
Responsible party
Sponsor
First posted
Sep 6, 2019
Start date
Jul 26, 2022
Primary completion
Mar 15, 2025 (estimated)
Completion
Jun 15, 2025 (estimated)
Last update
Feb 20, 2024

Study contacts

Yifang Cheng, PhD
Contact
yf@energenesis-biomedical.com
+886-2-2627-0835 ext. 701

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion